RankAlpha logo
Back to Rankings

BDSX

BiodesixD
Nasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-03
View Chart
Current thesis
If the Q1 2026 release confirms another clean revenue-growth quarter, maintains the FY2026 revenue framework introduced with Q4 2025 results, and shows cash usage continuing to moderate, BDSX can keep a speculative recovery case alive from a depressed market cap base.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -23.8.
What can break
As of May 4, 2026, the actual Q1 2026 earnings release was not yet confirmed on the company quarterly-results page, so the surprise and guidance read-through remain open.
Momentum
72
Value
36
Sentiment
25
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $11.50 · Bull $14.00 · Bear $8.00
Data freshness
Prices
As of 2026-06-03
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-03 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-04 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-03
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $30.00
Why
Momentum72 · Δ7d -23.8
Value36 · Δ7d -0.0
Sentiment25 · Δ7d -33.7
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
72
34% active weight
Current posture
7d trendSoftening
Δ7d
-23.8
Δ21d
-26.9
Value
36
32% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
25
33% active weight
Current posture
7d trendSoftening
Δ7d
-33.7
Δ21d
-23.7
Why this grade

Composite grade D. Momentum 72.1 / Value 36.3 / Sentiment 24.9

Fundamentals (TTM)
As of 2026-06-02
Market Cap
$159.89M
Beta
0.65
Shares Out
7.96M
P/E (TTM) · Derived
-4.3
P/S (TTM)
0.62
P/FCF (TTM) · Derived
-5.06
Rev YoY
+19.9%
EPS YoY
+17.1%
Gross Margin
+79.8%
Op Margin
-40.6%
Net Debt
$10.18M
Current Ratio
1.84
As of 2026-06-03 • Updated nightlySource: Internal modelMethodology